Pregnancy exposure to disease-modifying drugs in multiple sclerosis: a prospective study.

Abstract Background In multiple sclerosis (MS), fetal exposure to DME carries varying degrees of risk. We aim to analyze the clinical and obstetric outcomes of MS patients (MSp) exposed to DMDs during pregnancy. Methods Observational study. We analyzed clinical-obstetric data of a cohort MSp, who became pregnant between 2007-2017. They were prospectively followed during pregnancy and postpartum. Control group: healthy pregnant women (HPW). Results Sixty-eight pregnancies in MSp. Fifty-six HPW. Thirteen MSp were exposed to DMDs during pregnancy. Obstetric outcome: 2(15%) infants had low birth weight, no preterm deliveries. Fifty-five MSp were not exposed to DMDs: 22(40%) discontinued DMD before pregnancy, 33(60%) naive. Five infants (9%) had low birth weight and 7(12%) were preterm. HPW: 56. Low birth weight 6 (11%), preterm delivery 6 (11%). There were no differences in relapse incidence during pregnancy-puerperium between MSp groups. There were no differences in birth weight, gestation time, delivery-cesarean section. We found no special obstetric morbidity in women exposed to DMDs. Conclusions There were no significant differences in the clinical and obstetric variables analyzed between pregnant women exposed to DMDs, unexposed, and HPW.